Anticoagulant therapy control in primary healthcare setting

Abstract

The aim of the study was to evaluate efficiency anticoagulant therapy control in primary healthcare setting. The prospective, controlled study involved 301 patients with «non-valvular» atrial fibrillation, receiving various anticoagulant drugs in 2013–2015. After discharge the patients were advised to visit anticoagulant therapy control department. The risk of thromboembolic complications and the risk of bleeding were assessed with CHA2DS2VASc scale HAS-BLED, respectively. Major bleeding was assessed with TIMI scale. The time in therapeutic range for Warfarin was assessed for the patient taking warfarin. The study involved 301 patients with non-valvular atrial fibrillation taking anticoagulants: warfarin – 49 (16%), rivaroxaban – 34 (11%), apixaban – 81 (28%) and dabigatran –137 (45%). Minor bleeding was found in all groups. Large bleeding was found in patients receiving warfarin, dabigatran and rivaroxaban.

Keywords

• atrial fibrillation
• anticoagulant therapy
• bleeding